A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability

To compare the methods and baseline characteristics of the American Migraine Prevalence and Prevention (AMPP) and Chronic Migraine Epidemiology and Outcomes (CaMEO) studies.

• Publication year

  2016

• Venue

  Headache

• Publication date

  2016-06-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/head.12878PMID 27349336PMCID 5132024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study.

  2016cited by this paper
• Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

  2016influential reference
• The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results

  2015cited by this paper
• U.S. Smartphone Use in 2015

  2015cited by this paper
• Barriers to Chronic Migraine Care: Results of the CaMEO (Chronic Migraine Epidemiology & Outcomes) Study (P6.205)

  2014cited by this paper
• Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the American Migraine Prevalence and Prevention (AMPP) Study

  2014cited by this paper
• Randomized Trial of a Smartphone Mobile Application Compared to Text Messaging to Support Smoking Cessation

  2014cited by this paper
• Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

  2013cited by this paper
• Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features

  2013cited by this paper
• The Digital Divide Among Low-Income Homebound Older Adults: Internet Use Patterns, eHealth Literacy, and Attitudes Toward Computer/Internet Use

  2013cited by this paper
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study

  2013cited by this paper
• A Comparison of Two Delivery Modalities of a Mobile Phone-Based Assessment for Serious Mental Illness: Native Smartphone Application vs Text-Messaging Only Implementations

  2013cited by this paper
• Migraine life-time prevalence in mental disorders: concurrent comparisons with first-degree relatives and the general population.

  2012cited by this paper
• A Biography of the Pew Research Center’s Internet & American Life Project

  2012cited by this paper
• Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)

  2011cited by this paper
• The effect of health, socio-economic position, and mode of data collection on non-response in health interview surveys

  2010cited by this paper
• Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers

  2010cited by this paper
• Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study

  2009cited by this paper
• Statistics in Brief: The Importance of Sample Size in the Planning and Interpretation of Medical Research

  2008cited by this paper
• The International Classification of Headache Disorders

  2008cited by this paper
• Probable Migraine in the United States: Results Of The American Migraine Prevalence and Prevention (AMPP) Study

  2007cited by this paper
• Migraine prevalence, disease burden, and the need for preventive therapy

  2007cited by this paper
• Patterns of Medical Diagnosis and Treatment of Migraine and Probable Migraine in a Health Plan

  2006cited by this paper
• Prevalence and Diagnosis of Migraine in Patients Consulting Their Physician With a Complaint of Headache: Data From the Landmark Study

  2004cited by this paper
• Assessment of Migraine Disability Using the Migraine Disability Assessment (MIDAS) Questionnaire: A Comparison of Chronic Migraine With Episodic Migraine

  2003cited by this paper
• Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation Survey

  2003cited by this paper
• Migraine in the United States: Epidemiology and patterns of health care use

  2002cited by this paper
• Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II

  2001cited by this paper
• When to Use Web-based Surveys

  2000cited by this paper
• Migraine Without Aura and Migraine with Aura are Inherited Disorders

  1996cited by this paper
• Classification of daily and near-daily headaches

  1996cited by this paper
• Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

  1992cited by this paper

• Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America

  2026cites this paper
• Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis.

  2026cites this paper
• Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey

  2025cites this paper
• Clinical Characteristics of Migraine and Serum Beta-Endorphin Levels in Undergraduate Students in Osun State, Nigeria

  2025cites this paper
• Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)

  2025cites this paper
• Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

  2025cites this paper
• Prevalence of adverse childhood experiences in the refractory chronic migraine population compared to non‐refractory chronic and episodic migraine

  2025cites this paper
• Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study

  2025cites this paper
• Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant

  2025cites this paper
• Methodological challenges in using screening tools for depression in migraine: A systematic review

  2025cites this paper
• Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine

  2024cites this paper
• Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change

  2024cites this paper
• Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial

  2024cites this paper
• Patterns of migraine medication use in Norway: A nationwide registry-based observational study

  2024cites this paper
• Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials

  2024cites this paper
• Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan

  2024cites this paper
• MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment

  2024cites this paper
• Prevalence and burden of migraine in the United States: A systematic review

  2024cites this paper
• Associations between the burdens of comorbid sleep problems, central sensitization, and headache-related disability in patients with migraine

  2024cites this paper
• Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States

  2024influential citation
• Shared comorbidity of depression, migraine, insomnia, and fibromyalgia in a population-based sample.

  2024cites this paper
• Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse

  2024influential citation
• Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.

  2024cites this paper
• Management of medication overuse headache.

  2024cites this paper
• Update on gepants for the treatment of chronic migraine

  2024cites this paper
• The Chronic Headache Self‐Efficacy Scale: Development and assessment of measurement properties

  2024cites this paper
• Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

  2024cites this paper
• An Assessment of Sex and Gender Considerations in Migraine Calcitonin Gene-Related Peptide Clinical Trials

  2024cites this paper
• Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis

  2024cites this paper
• The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region

  2024cites this paper
• Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study

  2024cites this paper
• 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache

  2024cites this paper
• Zinc as An Emerging Therapy in the Management of Migraine: A Systematic Review.

  2024cites this paper
• Prevalence, characteristics, and treatment outcomes of migraine headache in Nigeria: a systematic review and meta-analysis

  2024cites this paper
• Sex differences in clinical characteristics of migraine and its burden: a population‐based study

  2023cites this paper
• Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine

  2023cites this paper
• Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews

  2023cites this paper
• Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial

  2023cites this paper
• Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care

  2023cites this paper
• Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

  2023cites this paper
• Sex-related differences in migraine clinical features by frequency of occurrence: a cross-sectional study

  2023cites this paper
• Characterisation of the management of patients with migraine in the primary care setting in Spain. Analysis of the results of the European My-LIFE anamnesis project.

  2023cites this paper
• Migraine Patient Care Model Preferences in a Community Practice.

  2023cites this paper
• Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review

  2023cites this paper
• Investigation of Frequency-Specific Loudness Discomfort Levels in Listeners With Migraine: A Case–Control Study

  2023cites this paper
• Greater occipital nerve blockade for the preventive treatment of chronic migraine: A randomized double-blind placebo-controlled study

  2023cites this paper
• Quality of Sleep and Disability Associated with Headache: Migraine versus Tension-Type Headache: A Comparative Study

  2023cites this paper
• Understanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017

  2023cites this paper
• Effects of onabotulinumtoxin A in patients concurrently diagnosed with chronic migraine encephalalgia and temporomandibular disorders: A retrospective case series

  2022cites this paper
• Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab

  2022cites this paper
• The effect of the COVID‐19 pandemic on headache‐related disability among young adults with migraine

  2022cites this paper
• Legal Aspects of Migraine in the Workplace

  2022cites this paper
• Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study.

  2022cites this paper
• Therapeutic applications and potential mechanisms of acupuncture in migraine: A literature review and perspectives

  2022cites this paper
• Epidemiology and treatment utilization for Canadian patients with migraine: a literature review

  2022cites this paper
• Association of Childhood Trauma with Migraines in Men

  2022cites this paper
• Characteristics and Gender Differences of Headache in the Veterans Health Administration

  2022cites this paper
• A stated preference survey to explore patient preferences for novel preventive migraine treatments

  2022cites this paper
• Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process

  2022cites this paper
• Sex and Gender Considerations in Episodic Migraine

  2022cites this paper
• Migraine in the workplace

  2022cites this paper
• Development and validation of a web-based headache diagnosis questionnaire

  2022cites this paper
• Practical Insights on the Identification and Management of Patients with Chronic Migraine

  2022cites this paper
• Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity

  2022cites this paper
• Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE)

  2022cites this paper
• The Primary Care Management of Headache: Synopsis of the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.

  2022cites this paper
• Caracterización del manejo del paciente con migraña en Atención Primaria en España. Análisis de los resultados del proyecto europeo My-LIFE anamnesis

  2022cites this paper
• Headache as a Neurologic Manifestation of Systemic Disease

  2022cites this paper
• Prevalence and impact of visual aura in migraine and probable migraine: a population study

  2022cites this paper
• TIME, to move forward? comment on “a universal outcome measure for headache treatments, care-delivery systems and economic analysis”

  2022cites this paper
• Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments

  2022cites this paper
• Plasma Lipolysis and Changes in Plasma and Cerebrospinal Fluid Signaling Lipids Reveal Abnormal Lipid Metabolism in Chronic Migraine

  2021cites this paper
• Current clinical practice in disabling and chronic migraine in the primary care setting: results from the European My-LIFE anamnesis survey

  2021cites this paper
• Prevalence, Disability, and Management Patterns of Migraine in Korea: Nationwide Survey Data from 2009 and 2018

  2021cites this paper
• Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden

  2021cites this paper
• Are there gender differences in neck pain and musculoskeletal disorders of the cervical spine associated with migraine?

  2021cites this paper
• Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

  2021cites this paper
• A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial

  2021cites this paper
• Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial

  2021cites this paper
• Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea

  2021cites this paper
• Safety and tolerability of preventive treatment options for chronic migraine

  2021cites this paper
• Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

  2021cites this paper
• Treatment Realities of Headache Disorders in Rural Germany by the Example of the Region of Western Pomerania

  2021cites this paper
• OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study

  2021cites this paper
• Early use of erenumab in US real-world practice

  2021cites this paper
• Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

  2021cites this paper
• Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

  2021cites this paper
• Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea

  2021cites this paper
• Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

  2021cites this paper
• Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium

  2021cites this paper
• Menopause hormone therapy, migraines, and thromboembolism.

  2021cites this paper
• Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study

  2021cites this paper
• Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.

  2021cites this paper
• Migraine and comorbidities

  2021cites this paper
• Sex-Specific Pharmacotherapy for Migraine: A Narrative Review

  2020cites this paper
• Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine

  2020cites this paper
• Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

  2020cites this paper
• [Migraine burden and clinical inertia: what can we do?]

  2020cites this paper
• Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis

  2020cites this paper
• Hypersensitivity to calcitonin gene-related peptide in chronic migraine

  2020cites this paper